Tonix Pharmaceuticals stock halted ahead of FDA approval news
BOSTON—Wendy B. Young, a member of the board of directors at Rapport Therapeutics , Inc. (NASDAQ:RAPP), has recently purchased 6,000 shares of the company’s common stock. The transaction, dated March 12, was executed at a weighted average price of $10.2083 per share, resulting in a total purchase value of $61,249. The purchase comes as RAPP shares have shown strong momentum, gaining nearly 24% in the past week, despite being down about 47% over the past six months.
The shares were acquired in multiple transactions, with prices ranging between $10.20 and $10.25 per share. This acquisition brings Young’s total direct ownership in the company to 6,000 shares.
Rapport Therapeutics, based in Boston, is known for its work in pharmaceutical preparations. This recent transaction reflects Young’s investment in the company’s future prospects.
In other recent news, Rapport Therapeutics has appointed Dr. Jeffrey Sevigny as its new chief medical officer. Dr. Sevigny brings over 15 years of experience in drug development, having previously held leadership roles at companies like Prevail Therapeutics (NASDAQ:PRVL) and Eli Lilly (NYSE:LLY). At Rapport, he will oversee the clinical strategy and progression of the company’s pipeline, with a particular focus on the RAP-219 program, which is in clinical trials for conditions such as focal epilepsy and bipolar mania. This appointment is expected to bolster Rapport’s clinical development efforts in its precision neuroscience pipeline.
Additionally, TD Cowen has highlighted Rapport Therapeutics as one of the companies to watch in 2025. The firm mentioned that Rapport is testing a new Phase II approach for RNS-associated conditions with RAP-219, with functional outcome score data expected by mid-year. This development is part of a broader list of biotech catalysts that TD Cowen anticipates will generate significant investor interest. These recent developments underscore the ongoing advancements and strategic changes at Rapport Therapeutics.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.